Charles River Laboratories International, Inc. $CRL Stock Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 150.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,746 shares of the medical research company’s stock after acquiring an additional 18,482 shares during the quarter. Nisa Investment Advisors LLC owned approximately 0.06% of Charles River Laboratories International worth $9,070,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after buying an additional 210,260 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares during the last quarter. Amundi increased its position in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares during the period. Van Berkom & Associates Inc. increased its position in Charles River Laboratories International by 11.2% during the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock worth $86,449,000 after acquiring an additional 50,462 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International by 230.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock valued at $59,044,000 after purchasing an additional 142,716 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $340.64 on Friday. The firm has a market cap of $16.26 billion, a price-to-earnings ratio of -70.24, a PEG ratio of 3.22 and a beta of 1.40. The company has a 50 day moving average of $293.05 and a 200-day moving average of $232.43. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $351.21.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CRL. Deutsche Bank Aktiengesellschaft boosted their price target on Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Mizuho lifted their price objective on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a report on Friday, September 25th. Royal Bank Of Canada boosted their price objective on Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Finally, BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $302.33.

Insider Buying and Selling

In other news, CAO Michael Knell sold 6,645 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares in the company, valued at $7,788,017.16. The trade was a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 91,971 shares of company stock valued at $26,033,968. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.